Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

L&G to sell US protection business to Meiji Yasuda for $2.3bn

(Sharecast News) - Legal & General is to sell its US protection business to Japanese peer Meiji Yasuda in a $2.3bn deal that will see the latter take a 5% stake in UK financial services group. L&G's chief executive António Simões called it a "transformative transaction" that will bring both significant strategic and financial benefits to the company.

Through the deal, Meiji Yasuda will own L&G's US protection business and take a 20% economic interest in its US Pension Risk Transfer (PRT) unit, with L&G retaining 80% of existing and new PRT through reinsurance arrangements.

The transaction will also kickstart a long-term strategic partnership between the two to support L&G's growth ambitions in US PRT and asset management.

Following completion, which is expected towards the end of 2025, £400m of proceeds from the deal will be used to fund the US PRT reinsurance arrangements, £1.0bn will be used for a new share buyback programme, while the remainder will be retained and invested, L&G said.

The additional repurchase of shares means L&G expects to return the equivalent of 40% of its market cap to shareholders over 2025-2027 through a combination of dividends and buybacks.

"This strategic partnership brings together two highly complementary global businesses, with a shared ambition for growth, and will enable us to capitalise on the large market opportunities in US Pension Risk Transfer while driving scale and profitability in global asset management," Simões said.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.